JNJ
JNJ dropped 5.7 percent today, and the counterintuitive part is worth understanding: they beat earnings and raised their full-year forecast. The problem is the raise wasn't enough. Wall Street had already priced in more aggressive guidance, and when J&J's updated outlook landed below those expectations, the stock got punished anyway. This is what traders call the whisper number effect — the official analyst consensus is one bar, but the market moves to a higher, unofficial one in the days before the print. Miss that invisible bar and it doesn't matter that you cleared the public estimate. The medtech division adds another layer: surgery revenues fell, and the company is now floating a spinoff as a potential fix. Two problems, one print. Watch whether that spinoff story develops — that's the next real catalyst here.
+2.1% — Johnson & Johnson CFO taps internal investment for medtech growth
-5.7% — Can a Spinoff Fix Johnson & Johnson’s Medtech Problem?
+1.9% — Coca-Cola (NYSE:KO) & Johnson & Johson (NYSE:JNJ): Buy Them For The Dividends, Says Jim Cramer
-2.3% — Johnson & Johnson vs. Eli Lilly: Which Pharma Stock Can Make Your Portfolio Healthier in 2026?
-1.6% — Johnson & Johnson (JNJ) Sees a More Significant Dip Than Broader Market: Some Facts to Know
-2.2% — Johnson & Johnson (JNJ) Sees a More Significant Dip Than Broader Market: Some Facts to Know
+2.0% — Johnson & Johnson (JNJ) Rises As Market Takes a Dip: Key Facts
-1.6% — I Think Johnson & Johnson Is the Best Dividend Stock to Buy Right Now
-2.2% — Moved with the tape — no single reported reason that day.
+3.3% — Moved with the tape — no single reported reason that day.
-3.7% — Johnson & Johnson Just Got FDA Clearance for Its Surgical Robot, Hiked Its Dividend for the 64th Time, and Is
+1.6% — FDA Approves Johnson & Johnson Table-Integrated OTTAVA Robotic Surgery System
+2.0% — FDA Approves Johnson & Johnson Table-Integrated OTTAVA Robotic Surgery System
-1.7% — Top Analyst Reports for Johnson & Johnson, Lam Research & Seagate
-2.7% — Johnson & Johnson (JNJ) Q2 2026 Earnings Call Highlights: Strong Sales Growth and Raised ...
-1.5% — Moved with the tape — no single reported reason that day.
-1.6% — Will Johnson & Johnson (JNJ) Beat Estimates Again in Its Next Earnings Report?
+3.1% — Johnson & Johnson (JNJ) Could Be 34% Below Fair Value Following IMAAVY Update
+3.6% — JNJ Stock Management Sees A Breakout, The Market Sees A Standoff
-1.8% — Why Is JNJ Stock Defying The Market’s Daily Mood Swings?
+1.5% — Moved with the tape — no single reported reason that day.
+4.0% — Johnson & Johnson (JNJ) Unveils IMAAVY Data That Could Expand Early gMG Use
+1.6% — Johnson & Johnson Earnings Preview: What to Expect
+3.4% — Moved with the tape — no single reported reason that day.
-2.5% — Moved with the tape — no single reported reason that day.
-2.2% — Moved with the tape — no single reported reason that day.
+2.1% — Moved with the tape — no single reported reason that day.
+2.0% — Moved with the tape — no single reported reason that day.
+2.2% — Moved with the tape — no single reported reason that day.
-2.4% — Moved with the tape — no single reported reason that day.
-1.8% — Assessing Johnson & Johnson (JNJ) Valuation After Guidance Raise Growth Initiatives And Talc Litigation Update
The brief, in your inbox
One email every market morning. What moved, why, and what happened after.